Filing Flows › Relay Therapeutics (RLAY) › Q2 2025
Relay Therapeutics (RLAY) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Relay Therapeutics (RLAY) reported revenue of $677K for the second quarter 2025 (Q2 2025) and -91% from the quarter before.
Relay Therapeutics, Q2 2025: revenue $677K, net loss $70.4M, operating cash flow −$55.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $677K | -91% | — |
| Operating profit | −$76.8M | — | — |
| Net earnings | −$70.4M | — | — |
| Operating cash flow | −$55.3M | — | — |
What changed
Revenue was $677K in Q2 2025, down 91% from the previous quarter.
Operating costs exceeded revenue by $76.8M, an operating margin of -11351.1%. The quarter ended with a net loss of $70.4M, narrower than the previous quarter's $77.1M loss.
Operating cash flow was −$55.3M. Non-cash charges added back $1.0M of depreciation and $14.5M of share-based compensation. Capital expenditures of $26K exceeded it, leaving free cash flow of −$55.3M.
Questions
What was Relay Therapeutics' revenue in the second quarter 2025?
Relay Therapeutics (RLAY) reported revenue of $677K for the second quarter 2025 (Q2 2025) and -91% from the quarter before.
Source: Relay Therapeutics 10-Q on SEC EDGAR.